Clinical study on liposomal paclitaxel/gemcitabine combined with cisplatin for the treatment of advanced non-small cell lung cancer
10.13699/j.cnki.1001-6821.2014.12.02
- VernacularTitle:紫杉醇脂质体或吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究
- Author:
Na LI
1
;
Zi-Yang HAN
;
Bin ZHENG
Author Information
1. 福建医科大学 附属协和医院 药学部
- Keywords:
liposomal paclitaxel;
gemcitabine;
cisplatin;
non-small cell lung cancer
- From:
The Chinese Journal of Clinical Pharmacology
2014;(12):1083-1085
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of liposomal paclitaxel/gemcitabine combined with cisplatin on advanced non-small cell lung cancer ( NSCLC ).Methods Sixty -eight cases with advanced NSCLC were recruited and randomly divided into LP group ( n=34 ) and GP group ( n=34 ).Patients in the LP group were given liposomal paclitaxel 135 mg· m-2 and cisplatin 75 mg· m-2 on the first day by intravenous infusion.Patients in the GP group were given gemci-tabine 1000 mg · m-2 on the first and eighth day and cisplatin 75 mg· m-2 on the first day by intravenous infusion.The treatment lasted for twenty-one days.The clinical efficacy , survival time and adverse re-actions were compared between the two groups.Results There were no statistical difference in the aspects of objective response rate and disease control rate in the primary lesions of the two groups ( P>0.05 ).But the objective response rate of lymph node in LP group (44.1%) , the medi-an survival time (17 months), and one-year survival rate in LP group were higher than those in the GP group ( P<0.05 ).The incidences of gastrointestinal reactions and thrombocytopenia in LP group were much lower than those in GP group ( P<0.05 ) .The adverse reactions of liver and kidney dysfunction , neutropenia , anemia , allergies and hair loss in two groups had no statistical differences ( P<0.05 ).Conclusion Liposomal paclitaxel combined with csiplatin can improve the median survival period of advanced non -small cell lung cancer patients and decrease adverse reactions.
